Beyondspring Inc. (BYSI) — SEC Filings
Beyondspring Inc. (BYSI) — 26 SEC filings. Latest: 8-K (Mar 25, 2026). Includes 10 8-K, 8 6-K, 3 10-Q.
View Beyondspring Inc. on SEC EDGAR
Overview
Beyondspring Inc. (BYSI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: BeyondSpring Inc. filed an 8-K on March 25, 2026, reporting on its results of operations and financial condition, as detailed in Item 2.02 and an accompanying press release (EX-99.1). This filing indicates the company is providing an update on its financial performance. For investors, this matters b
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 19 neutral, 3 mixed. The dominant filing sentiment for Beyondspring Inc. is neutral.
Filing Type Overview
Beyondspring Inc. (BYSI) has filed 10 8-K, 3 10-Q, 1 DEF 14A, 1 10-K, 2 SC 13G/A, 8 6-K, 1 20-F with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of BYSI's 18 recent filings, 4 were flagged as high-risk, 7 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $1.131M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $12.483M |
| Operating Margin | N/A |
| Total Assets | $29.484M |
| Total Debt | $49.294M |
Key Executives
- Mr. Linqing Jia
- Dr. Lan Huang
- Dr. Quanqi Song
- G. Kenneth Lloyd
- June Lu
Industry Context
BeyondSpring operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on developing innovative cancer therapies. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on clinical trial outcomes and market adoption of novel treatments.
Top Tags
Biotechnology (3) · financial-results (2) · Clinical Trials (2) · R&D Expenses (2) · material-agreement (2) · filing (2) · corporate-event (2) · corporate-governance (2) · Pharmaceuticals (2) · acquisition (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income attributable to BeyondSpring Inc. | $1.131M | For the nine months ended September 30, 2025, a significant improvement from a $9.394 million net loss in the prior year, driven by asset sales. |
| Gain on sale of subsidiary interests | $6.986M | Key factor in the nine-month net income, stemming from the sale of SEED Therapeutics Inc. shares. |
| Cash and cash equivalents | $12.483M | As of September 30, 2025, a substantial increase from $2.922 million at December 31, 2024, bolstering liquidity. |
| Net loss | $4.944M | For the three months ended September 30, 2025, indicating ongoing operational losses. |
| Accumulated deficit | $406.294M | As of September 30, 2025, highlighting the company's historical unprofitability. |
| Revenue | $0 | For both the three and nine months ended September 30, 2025, underscoring the company's pre-commercial stage. |
| Research and development expenses | $1.039M | For the three months ended September 30, 2025, an increase from $0.622 million in the prior year, reflecting continued investment. |
| Ordinary shares outstanding | 40,322,320 | As of September 30, 2025, indicating the total number of shares in circulation. |
| Net loss for Q2 2025 | $4.649M | Increased from $4.089M in Q2 2024, indicating continued operational losses. |
| Net loss for H1 2025 | $3.479M | Significantly improved from $7.377M net loss in H1 2024, primarily due to a one-time gain. |
| Cash and cash equivalents as of June 30, 2025 | $9.544M | Increased from $2.922M at December 31, 2024, largely due to investing activities. |
| Net cash provided by investing activities for H1 2025 | $17.154M | Primarily from proceeds of subsidiary sale and short-term investment maturities. |
| Research and development expenses for Q2 2025 | $1.002M | Increased from $0.829M in Q2 2024, reflecting ongoing drug development. |
| Revenue for Q2 2025 and H1 2025 | $0 | Indicates no commercialized products generating income. |
| Net cash used in operating activities for H1 2025 | $10.072M | Highlights continued operational cash burn despite the one-time gain. |
Frequently Asked Questions
What are the latest SEC filings for Beyondspring Inc. (BYSI)?
Beyondspring Inc. has 26 recent SEC filings from Jan 2024 to Mar 2026, including 10 8-K, 8 6-K, 3 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BYSI filings?
Across 26 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 19 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Beyondspring Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Beyondspring Inc. (BYSI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Beyondspring Inc.?
Key financial highlights from Beyondspring Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BYSI?
The investment thesis for BYSI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Beyondspring Inc.?
Key executives identified across Beyondspring Inc.'s filings include Mr. Linqing Jia, Dr. Lan Huang, Dr. Quanqi Song, G. Kenneth Lloyd, June Lu.
What are the main risk factors for Beyondspring Inc. stock?
Of BYSI's 18 assessed filings, 4 were flagged high-risk, 7 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Beyondspring Inc.?
Forward guidance and predictions for Beyondspring Inc. are extracted from SEC filings as they are enriched.